Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA®
Decision brief
Answer first · skim in under a minute
Merz Therapeutics has entered an exclusive agreement with Kvvit for INBRIJA® (levodopa inhalation powder). This partnership marks a significant regulatory update in the pharmaceutical landscape.
Merz Therapeutics and Jiangxi Kvvit Pharmaceutical signed an exclusive license for INBRIJA (levodopa inhalation powder) in mainland China, Hong Kong and Macao. The deal expands Merz's Parkinson's franchise into Greater China while leaving approval contingent on local development.
Contents9 sections
Key Takeaways
- Exclusive license covers INBRIJA and its inhalation device for intermittent treatment of OFF episodes in adults with Parkinson's disease on levodopa/DDI therapy.
- Territory: mainland China, Hong Kong and Macao; product not yet approved there.
- Merz receives upfront, development and commercial milestones plus tiered supply and royalty economics; Kvvit funds local clinical and regulatory work.
- No manufacturing rights transfer to Kvvit; Merz remains supply and quality owner.
What did Merz and Kvvit announce?
According to the May 2026 Business Wire announcement, Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. entered an exclusive license and collaboration for INBRIJA in the licensed territory.
INBRIJA is positioned for intermittent treatment of episodic motor fluctuations (OFF episodes) in adult Parkinson's patients already treated with a levodopa/dopa-decarboxylase inhibitor. Earlier unsourced copy that left the territory as “M.” is corrected here.
How are roles and economics split?
Kvvit will lead development, regulatory activities and commercialization under a jointly agreed China Development Plan and will serve as Domestic Responsible Person. Merz will supply product, retain global product quality and key regulatory responsibilities, and act as Overseas Holder of the Drug Registration Certificate.
- Merz economics: upfront payment, development milestones, commercial milestones, tiered supply and royalty arrangements.
- Manufacturing: rights not granted to Kvvit.
- Dollar amounts for the 2026 Kvvit deal were not disclosed in the wire.
Why does Greater China access matter for Parkinson's care?
China's aging population is expected to drive large Parkinson's caseloads this decade, making inhaled on-demand levodopa a potential adjunct to oral regimens if regulators clear local data. Until then, Merz's revenue from the territory remains contingent.
Merz previously consolidated INBRIJA ownership through its July 2024 $185 million Acorda asset purchase, which provides the upstream product control enabling outbound regional licenses.
What should BD teams watch in diligence?
Confirm that local bridging or China-specific trials are funded, that device-drug combination requirements are mapped to NMPA expectations, and that supply agreements protect Merz quality oversight. Competitive OFF-episode therapies will contest the same neurologist channel once approved.
Investors should not model China sales until clinical and regulatory milestones are public; the wire states approval depends on successful development and review in the licensed territory.
What remains unproven?
The announcement is a license, not a marketing authorisation. No China pivotal efficacy package, launch date, or pricing is disclosed. Milestone values and royalty tiers remain private, so financial models need sensitivity ranges rather than point estimates.
Related NovaPharma coverage
- AI Organoids Target Parkinson's Disease Pathways
- Life Sciences Dealmaking Gains Strategic Momentum
- 2026 Cell Therapy Regulatory Landscape
Frequently Asked Questions
What territory does the Merz–Kvvit INBRIJA agreement cover?
The exclusive license and collaboration covers mainland China, Hong Kong and Macao for INBRIJA (levodopa inhalation powder) and its proprietary inhalation device for OFF episodes in Parkinson's disease.
Is INBRIJA already approved in China under this deal?
No. Merz and Kvvit stated INBRIJA is not currently approved in mainland China, Hong Kong or Macao; any approval depends on successful local clinical development and regulatory review.
Who manufactures and who commercializes under the agreement?
Merz supplies INBRIJA, retains global product quality responsibility, and acts as Overseas Holder of the Drug Registration Certificate. Kvvit leads local development, regulatory filings and commercialization; manufacturing rights are not granted to Kvvit.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for INBRIJA.
Unlock full calendar →Merz Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
- Drug INBRIJA Explore
- Drug levodopa Explore
- Company Merz Therapeutics Explore
- Company Kvvit Explore
- Patent US 12370163 — Levodopa dosing regimen Explore
- Patent US 12303481 — Levodopa dosing regimen Explore
- Patent US 12303482 — Levodopa dosing regimen Explore
- Patent US 12295931 — Levodopa dosing regimen Explore
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
